ARTICLE
15 September 2012

Product Liability: High Court ends Australian Vioxx litigation

The High Court refused special leave, suggesting that it did not consider that the applicant could establish causation.
Australia Consumer Protection
To print this article, all you need is to be registered or login on Mondaq.com.

Peterson v Merck Sharp & Dohme (Australia) Pty Ltd [2012] HCATrans 105

In the March 2012 edition of Insurance Update we reported on the judgment of the Federal Court in the appeal of the representative (class) action brought on behalf of certain consumers of the arthritic drug, Vioxx. Vioxx was alleged to have caused adverse cardiovascular side-effects in several arthritis patients. In October 2011, the Full Court of the Federal Court allowed the appeal against the earlier damages award against the supplier of Vioxx. See our article on the Federal Court appeal judgment here.

In the wake of the Federal Court appeal judgment, the lead applicant in the class action, Graham Peterson (a consumer of Vioxx), applied for special leave to appeal to the High Court. On 11 May 2012 the High Court (comprising French CJ and Crennan J) refused special leave to appeal. Given it was a special leave application, no reasons were given by the High Court, other than a statement from French CJ that "the applications are not suitable vehicles for the consideration of the questions of principle which would warrant the grant of special leave".

The transcript of the argument of the special leave application indicates that the determination centred on the issue of causation. Comments from the bench during the argument suggest that the High Court may have accepted submissions to the effect that it was simply not open to the trial judge to be satisfied on the facts that Vioxx had caused Mr Peterson's heart attack, having regard to the evidence of other possible causes, in particular age, gender, hypertension, hyperlipidemia, obesity, left ventricular hypertrophy and a history of smoking.

As discussed in our earlier article, the High Court's recent treatment of causation cases (e.g. Adeels Palace Pty Limited v Moubarak1, Amaca Pty Limited v Ellis2, and Tabet v Gett3) meant that a successful appeal was always going to be difficult for Peterson. The brief comment of French CJ in refusing special leave suggests that the High Court did not consider that Peterson could establish causation, regardless of how the causation test was framed, so did not see any merit in granting special leave. However, the comment, together with the forthcoming changes to the High Court leaves it open to the suggestion that the High Court may be prepared to again revisit causation in the near future if the appropriate case comes before it.

Footnotes

1(2009) 239 CLR 426
2(2010) 240 CLR 11
3(2010) 240 CLR 537

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
15 September 2012

Product Liability: High Court ends Australian Vioxx litigation

Australia Consumer Protection
Contributor
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More